PRFX (painreform.com) Prakiraan pendapatan perusahaan
The market value of PainReform Ltd. (PRFX) already prices in liquidity shortages and small-cap biotech risks. This chart of the company's future trading volume, sourced from the GURU.Markets terminal, identifies 0.00 as the current benchmark. Patents for the Plex03 technology ensure business stability, while management's lean approach to research aims to confirm the efficacy of pain management systems under strict FDA oversight.
PainReform Ltd (PRFX) - rincian metrik lan laporan keuangan
- nilai saham lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas PainReform Ltd.|PRFX - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas PainReform Limited|PRFX - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku PainReform Ltd|PRFX - Utang jangka dawa|Utang jangka cendhak perusahaan PainReform|Likuiditas cepet painreform.com
- statistik bathi lan rasio pasar:
PRFX - Penghasilan resik perusahaan|Bathi sing dikarepake PainReform Ltd.|PRFX - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep PainReform|PRFX - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PainReform Ltd|PRFX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan PainReform|PRFX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan painreform.com|PRFX - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep PainReform Ltd.
- indikator volume dodolan lan pendapatan:
Pambiji fundamental:PainReform Ltd.
Professional capital evaluates the profile of PainReform Ltd. (PRFX) through the lens of sustainable revenue growth. This indicator filters out market noise, revealing the long-term trajectory of product implementation. By analyzing the dynamics of the company's prospective sales, investors see the expansion potential of the PRF-110 platform into surgical protocols. High switching costs for clinics ensure the stability of this trend. The positive slope of the curve confirms the fundamental reliability of the asset.
Pesaing PainReform Ltd. (PRFX)
Prakiraan pendapatan perusahaan Haleon plc (HLN)|KVUE (kenvue.com) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Verona Pharma VRNA|MENS (Jyong Biotech Limited) - Pendapatan sing dikarepake perusahaan|Ligand Pharma - Prakiraan volume dodolan|AMRX - Prakiraan volume dodolan|PRGO: Prakiraan volume dodolan|ALVO - Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Liquidia|Prakiraan pendapatan perusahaan GLPG (Galapagos N.V.)|Prakiraan pendapatan perusahaan ANI Pharma (ANIP)|MNKD (Afrezza) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan AMPH (Amphastar Pharmaceuticals)|pacira.com (PCRX) - Volume dodolan sing dikarepake perusahaan|ARS Pharmaceuticals, Inc. - Prakiraan volume dodolan|Pendapatan sing dikarepake perusahaan TBPH|Aquestive Pharma (AQST) - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan scPharmaceuticals (SCPH)|Prakiraan pendapatan perusahaan Tectonic Therapeutic Inc.|TNXP: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan China SXT Pharmaceuticals (SXTC)|Volume dodolan mangsa ngarep perusahaan eupraxiapharma.com EPRX|BioHarvest - Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan EXOZ|ORMP - Prakiraan pendapatan perusahaan|ENTX: Prakiraan pendapatan perusahaan|HYFT (MindWalk Holdings Inc.) - Volume dodolan mangsa ngarep perusahaan|ABVC: Prakiraan volume pendapatan perusahaan|CPIX (Cumberland Pharma) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan QNTM (Quantum BioPharma Corp)|Volume dodolan mangsa ngarep perusahaan FGEN (FibroGen, Inc.)|Dodolan mangsa ngarep perusahaan telomirpharma.com|Prakiraan pendapatan perusahaan Rani Therapeutics Holdings, Inc. RANI|SNYR (Synergy CHC Corp.) - Pendapatan sing dikarepake perusahaan|RLYB - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan LEXX (Lexaria Bioscience)|PULM: Prakiraan volume dodolan|Pendapatan sing dikarepake perusahaan PTHL (Pheton Holdings)|Volume dodolan mangsa ngarep perusahaan APM|Prakiraan pendapatan perusahaan LYRA (Lyra Therapeutics Inc.)|Prakiraan pendapatan perusahaan Impact BioMedical (IBO)|TNFA: Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan YCBD (cbdMD)|Pendapatan mangsa ngarep perusahaan CYTO|Lipella Pharmaceuticals, Inc. - Prakiraan volume dodolan|OPTN - Prakiraan volume dodolan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Procaps Group Corp - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Petros Pharmaceuticals|Volume dodolan mangsa ngarep perusahaan qlsyy.net (QLI)|Prakiraan volume dodolan SLRN|Prakiraan volume dodolan TFF Pharmaceuticals Inc. (TFFP)
